# US Dural Arteriovenous Fistulas Treatment Market

> United States Dural Arteriovenous Fistulas Treatment Market Research Report: Size, Share, Trend Analysis - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.41%
- **2024:** $ 563.9 Million
- **2025:** $ 605.69 Million
- **2035:** $ 1,237.93 Million
- **Key Players:** Medtronic (IE), Stryker (US), Johnson & Johnson (US), Boston Scientific (US), Terumo (JP), B. Braun (DE), Abbott (US), Penumbra (US)

**Report ID:** MRFR/Pharma/16782-HCR · **Pages:** 100 · **Author:** Vikita Thakur · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-dural-arteriovenous-fistulas-treatment-market-18310

---

## Market Summary

## US Dural Arteriovenous Fistulas Treatment Market Highlighted Trends & Dynamics

The demand for treatments related to Dural Arteriovenous Fistulas (DAVF) in the United States has garnered attention due to the complexity and potential complications associated with this vascular disorder. Dural arteriovenous fistulas are abnormal connections between arteries and veins within the dura mater, the outermost layer of the brain covering. These abnormal connections can lead to symptoms such as headaches, neurological deficits, and, in severe cases, intracranial hemorrhage. The need for effective interventions to manage DAVF has increased in the US healthcare landscape, reflecting the growing awareness of this condition and the quest for comprehensive treatment options.

One of the key drivers of the demand for DAVF treatments is the potential for serious neurological complications if left untreated. DAVF poses the risk of increased pressure within the brain, leading to symptoms ranging from persistent headaches to more severe neurological deficits. The urgency to address these potential complications has fueled the demand for therapeutic interventions that aim to alleviate symptoms, reduce the risk of hemorrhage, and improve overall patient outcomes.

Advancements in medical imaging and diagnostic capabilities have played a crucial role in shaping the US DAVF treatment market. Improved imaging techniques, such as digital subtraction angiography and magnetic resonance angiography, enable healthcare providers to accurately diagnose and characterize DAVFs. Early and precise diagnosis is essential for determining the optimal treatment approach, contributing to the overall demand for effective interventions in managing DAVF.

The impact of DAVF on the quality of life and long-term outcomes for affected individuals further intensifies the demand for comprehensive treatment options. As patients with DAVF experience neurological symptoms that can significantly affect their daily functioning, there is a growing emphasis on interventions that not only address the underlying vascular abnormality but also improve overall neurologic well-being. The demand for treatments that offer a holistic approach to managing DAVF aligns with the broader healthcare trend towards patient-centered care and improved quality of life.

The rarity and complexity of DAVF contribute to the demand for specialized and multidisciplinary treatment approaches. Neurosurgeons, interventional neuroradiologists, and other specialists collaborate to determine the most appropriate course of action for each individual case. The demand for expertise in managing DAVF has led to the development of specialized centers and teams dedicated to the comprehensive care of patients with this vascular disorder.

Economic considerations, including healthcare costs and insurance coverage, also play a role in shaping the demand for DAVF treatments. Individuals seek accessible and cost-effective solutions for the diagnosis and management of DAVF, and healthcare providers explore strategies to address economic barriers to care. The demand for affordable and efficient treatment options aligns with the broader healthcare trends emphasizing value-based care and improved patient outcomes.

Moreover, research and advancements in treatment modalities contribute to the demand for innovative approaches to managing DAVF. Endovascular techniques, such as embolization, and surgical interventions are continuously evolving, offering more targeted and less invasive options for treating DAVF. The demand for cutting-edge treatments that combine efficacy with reduced invasiveness reflects the healthcare industry's commitment to advancing the field of vascular neurology and improving outcomes for patients with DAVF.

## Market Drivers

### Emerging Research and Clinical Trials

The surge in research and clinical trials focused on dural arteriovenous fistulas is a significant driver for the dural arteriovenous-fistulas-treatment market. Ongoing studies aim to explore new treatment modalities and improve existing therapies, which could lead to breakthroughs in patient care. As of November 2025, numerous clinical trials are underway, investigating various approaches to managing DAVFs, including novel pharmacological agents and advanced surgical techniques. The results of these trials may provide valuable insights that enhance treatment efficacy and safety. Consequently, the dural arteriovenous-fistulas-treatment market is likely to expand as new evidence-based practices emerge, ultimately benefiting patients and healthcare providers alike.

### Growing Focus on Patient-Centric Care

The shift towards patient-centric care in the US healthcare system is influencing the dural arteriovenous-fistulas-treatment market. This approach emphasizes personalized treatment plans and improved patient engagement, which can lead to better health outcomes. As healthcare providers increasingly prioritize patient preferences and experiences, there is a growing demand for treatments that align with these values. This trend is likely to drive the development of innovative therapies and enhance the overall quality of care for patients with DAVFs. Furthermore, patient-centric initiatives may lead to increased awareness and education about dural arteriovenous fistulas, further stimulating market growth as more individuals seek treatment.

### Advancements in Minimally Invasive Techniques

The development of minimally invasive techniques for treating dural arteriovenous fistulas is significantly influencing the dural arteriovenous-fistulas-treatment market. Innovations such as endovascular embolization have emerged as effective alternatives to traditional surgical methods, offering reduced recovery times and lower complication rates. These advancements not only enhance patient outcomes but also attract more patients seeking treatment. According to recent data, minimally invasive procedures have shown success rates exceeding 90%, which is likely to encourage healthcare providers to adopt these techniques more widely. As a result, the dural arteriovenous-fistulas-treatment market is poised for growth, driven by the increasing preference for less invasive options among both patients and clinicians.

### Rising Incidence of Dural Arteriovenous Fistulas

The increasing incidence of dural arteriovenous fistulas (DAVFs) in the US is a primary driver for the dural arteriovenous-fistulas-treatment market. Recent studies indicate that the prevalence of DAVFs has been on the rise, with estimates suggesting that approximately 1-2 cases per 100,000 individuals are diagnosed annually. This growing patient population necessitates advanced treatment options, thereby propelling market growth. As healthcare providers become more adept at diagnosing these conditions, the demand for effective treatment modalities is likely to increase. Furthermore, the aging population, which is more susceptible to vascular disorders, contributes to the rising incidence of DAVFs. Consequently, the dural arteriovenous-fistulas-treatment market is expected to expand as healthcare systems adapt to meet the needs of this growing demographic.

### Increased Investment in Healthcare Infrastructure

The ongoing investment in healthcare infrastructure in the US is a crucial driver for the dural arteriovenous-fistulas-treatment market. With healthcare facilities expanding and modernizing, there is a greater capacity to diagnose and treat complex conditions such as DAVFs. Reports indicate that healthcare spending in the US is projected to reach $6 trillion by 2027, which includes significant allocations for neurosurgical advancements. This influx of funding is likely to enhance the availability of cutting-edge technologies and treatment options, thereby improving patient access to care. As healthcare systems evolve, the dural arteriovenous-fistulas-treatment market is expected to benefit from improved facilities and resources dedicated to treating these conditions.

## Future Outlook

The [Dural Arteriovenous Fistulas Treatment Market](https://www.marketresearchfuture.com/reports/dural-arteriovenous-fistulas-treatment-market-4589) is projected to grow at a 7.41% CAGR from 2025 to 2035, driven by technological advancements and increasing patient awareness.

**New opportunities:**

- Development of minimally invasive treatment devices
- Expansion of telemedicine platforms for remote consultations
- Partnerships with insurance providers for better coverage options

By 2035, the market is expected to achieve substantial growth and enhanced treatment accessibility.

## Segment Insights

### By Treatment Type: Endovascular Intervention (Largest) vs. Surgery (Fastest-Growing)

In the US dural arteriovenous-fistulas-treatment market, Endovascular Intervention holds the largest market share, due to its minimally invasive nature and increasing preference among healthcare professionals. Surgery also remains a significant option, but it is experiencing a faster growth rate as advancements in surgical techniques and technologies make it more appealing to patients. Radiation Therapy and Medication, while present in the market, represent smaller shares and growth compared to these two dominant treatments.

The growth trends in the treatment type segment are primarily driven by technological advancements and increasing awareness among patients about their options. Endovascular Intervention benefits from continuous innovation, leading to improved outcomes and shorter recovery times. Surgery is emerging faster due to a rise in complex cases being referred for operative management, supported by training and improvements in surgical skill sets. This dynamic creates opportunities for both treatment modalities in the evolving landscape of dural arteriovenous-fistulas care.

Endovascular Intervention (Dominant) vs. Surgery (Emerging)

Endovascular Intervention is the dominant treatment modality in the US dural arteriovenous-fistulas-treatment market, characterized by its minimally invasive approach, which results in reduced recovery times and lower complication rates. This treatment has rapidly gained acceptance among neuro-interventionalists and patients alike, leading to increased adoption. On the other hand, Surgery is considered an emerging segment, gaining traction due to improved surgical techniques and enhanced training for surgical teams. As surgeons become more adept at tackling complex cases, surgical options are becoming more viable, leading to an uptick in referrals for surgical intervention. Both modalities are important, each catering to specific patient needs while contributing to the overall growth and evolution of the market.

### By Procedure Type: Transarterial Embolization (Largest) vs. Surgical Excision (Fastest-Growing)

The US dural arteriovenous-fistulas-treatment market is characterized by distinct procedure types, with Transarterial Embolization holding the largest share. This technique is preferred for its minimally invasive nature and effectiveness in occluding abnormal blood vessels. In contrast, Surgical Excision, although representing a smaller portion of the market, is experiencing rapid growth due to advancements in surgical techniques and increased awareness among healthcare providers about its efficacy in complex cases.

Growth trends in this segment are driven by technological advancements and an increasing patient population. The rising incidence of dural arteriovenous fistulas has prompted healthcare systems to enhance treatment options, leading to improved adoption of both Transarterial Embolization and Surgical Excision. Additionally, increasing research and clinical trials aiming to optimize these procedures contribute to their growing prominence in the US dural arteriovenous-fistulas-treatment market.

Transarterial Embolization (Dominant) vs. Surgical Excision (Emerging)

Transarterial Embolization remains the dominant procedure in the US dural arteriovenous-fistulas-treatment market due to its effectiveness and minimal recovery time. This technique allows for targeted treatment of vascular malformations, utilizing embolic agents to occlude affected vessels without the need for extensive surgery. In contrast, Surgical Excision is emerging as a vital alternative, particularly in cases where embolization is not feasible. The growing adoption of innovative surgical techniques is enhancing its reputation, making it a compelling choice for challenging cases. As healthcare professionals become more skilled in these methods, the balance between the two approaches may shift, highlighting the dynamic nature of the treatment landscape.

### By Diagnosis Type: Magnetic Resonance Imaging (Largest) vs. Computed Tomography (Fastest-Growing)

In the US dural arteriovenous-fistulas-treatment market, Magnetic Resonance Imaging (MRI) holds a significant market share as the leading diagnosis method. Its non-invasive nature and high-quality imaging contribute to its dominance amongst healthcare professionals. Computed Tomography (CT), while having a smaller share, is rapidly growing due to advancements in technology, enhancing its accuracy, and the increasing prevalence of conditions requiring timely diagnosis.

Growth trends in this segment indicate a rising preference for MRI due to its ability to provide detailed anatomical information. However, the swift adoption of CT imaging showcases its appeal in emergency settings where speed is vital. Increased investments in healthcare infrastructure and the need for innovative diagnostic solutions are significant drivers for the growth of both MRI and CT modalities.

Imaging: MRI (Dominant) vs. CT (Emerging)

Magnetic Resonance Imaging (MRI) is a pivotal technology in the US dural arteriovenous-fistulas-treatment market, renowned for its capability to produce detailed images of soft tissues and blood vessels without the need for ionizing radiation. Its non-invasive approach makes it a preferred option for diagnosing dural arteriovenous fistulas. In contrast, Computed Tomography (CT) is gaining traction as an emerging modality, particularly in acute situations where rapid assessment is crucial. Advances in CT technology have led to enhanced image clarity and reduced scan times, rendering it an attractive alternative in emergency departments. The interplay of these modalities highlights a dynamic diagnostic landscape driven by both established practices and innovative developments.

### By Patient Type: Adult (Largest) vs. Pediatric (Fastest-Growing)

The distribution of market share in the US dural arteriovenous-fistulas-treatment market indicates that the Adult patient segment commands the largest portion, largely driven by the higher prevalence of dural arteriovenous fistulas in older demographics. Interventional procedures targeted towards adults have been developed more extensively, leading to their dominant position in the treatment landscape. Conversely, the Pediatric segment, while smaller in share, is rapidly expanding due to increasing awareness and advancements in pediatric-specific treatment methodologies.

Growth trends in the Patient Type segment reveal a significant rise in the Pediatric patient category. This growth is driven by enhanced diagnostic techniques, increased healthcare access, and rising investment in pediatric healthcare services. Moreover, the growing emphasis on tailored therapies for children highlights the market's potential, further encouraging innovation and development in the Pediatric segment, positioning it as a focal point for future growth in the treatment landscape.

Adult (Dominant) vs. Pediatric (Emerging)

In the context of the US dural arteriovenous-fistulas-treatment market, the Adult segment is characterized by its established protocols and a wide range of treatment options suited for older patients. The dominance of this segment is attributed to the prevalence of fistulas within adult populations who often seek interventional therapy. On the other hand, the Pediatric segment, while currently smaller, is considered emerging due to the growing focus on child-specific health complications and treatment methods. Enhanced research and dedicated healthcare resources towards pediatric care are driving innovation, making it an increasingly important area of attention for healthcare providers and stakeholders in the market. As these segments evolve, understanding their unique challenges and opportunities will be essential for effective market strategies.

### By Healthcare Setting: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the US dural arteriovenous-fistulas-treatment market, hospitals hold the largest market share, driven by their comprehensive resources and advanced technology. Ambulatory surgical centers, while smaller in market share compared to hospitals, are rapidly gaining traction due to their efficiency and cost-effectiveness, appealing to both providers and patients. Specialized clinics represent a niche segment, focusing on targeted treatments but lacking the scale of hospitals and the accessibility of ambulatory centers.

Growth trends indicate that the preference for outpatient procedures is shifting towards ambulatory surgical centers, influenced by patients' desire for lower costs and faster recovery times. Additionally, advancements in minimally invasive techniques are enhancing the demand for specialized clinics as they expand the range of treatments available outside traditional hospital settings. This evolution showcases a dynamic transformation in healthcare delivery for dural arteriovenous fistulas.

Hospitals (Dominant) vs. Specialized Clinics (Emerging)

Hospitals, as the dominant players in the US dural arteriovenous-fistulas-treatment market, benefit from extensive infrastructures and multi-disciplinary teams that facilitate comprehensive care for complex conditions. They are equipped with state-of-the-art technologies and have established protocols that ensure high-quality treatment outcomes. In contrast, specialized clinics are emerging as important alternatives in the treatment landscape. These clinics often focus on innovative and targeted treatment methods, providing more personalized care and shorter wait times. However, they face challenges regarding patient outreach and awareness compared to hospitals. The growth of specialized clinics is anticipated to be driven by patients seeking tailored treatment options and the increased prevalence of less invasive procedures.

## Competitive Benchmarking

The dural arteriovenous-fistulas-treatment market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Medtronic (IE), Stryker (US), and Boston Scientific (US) are actively pursuing strategies that emphasize technological advancements and enhanced patient outcomes. Medtronic (IE), for instance, has focused on integrating advanced imaging technologies into its treatment protocols, thereby improving procedural accuracy and patient safety. Meanwhile, Stryker (US) has been expanding its product portfolio through strategic acquisitions, which allows it to offer a more comprehensive range of solutions for vascular conditions. Collectively, these strategies not only enhance the competitive positioning of these companies but also drive overall market growth by fostering a culture of innovation and responsiveness to patient needs.In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. This approach appears to be particularly effective in a moderately fragmented market where agility can provide a competitive edge. The presence of multiple players, including Johnson & Johnson (US) and Abbott (US), contributes to a dynamic environment where collaboration and competition coexist. The collective influence of these key players is significant, as they work to establish standards and best practices that shape treatment protocols across the industry.

In October  Boston Scientific (US) announced the launch of a new catheter designed specifically for the treatment of dural arteriovenous fistulas. This innovative device is expected to enhance the precision of embolization procedures, thereby improving patient outcomes. The introduction of this product underscores Boston Scientific's commitment to advancing treatment options and reflects a broader trend towards specialization in medical devices. Such innovations are likely to strengthen the company's market position and attract a wider range of healthcare providers.

In September  Stryker (US) entered into a partnership with a leading academic institution to develop next-generation imaging technologies for vascular interventions. This collaboration aims to leverage cutting-edge research to enhance the efficacy of existing treatment modalities. By aligning with academic experts, Stryker (US) not only enhances its R&D capabilities but also positions itself at the forefront of technological advancements in the field. This strategic move may lead to breakthroughs that redefine treatment standards and improve patient care.

In August  Medtronic (IE) expanded its operations in the US by establishing a new manufacturing facility dedicated to vascular products. This investment is indicative of Medtronic's long-term commitment to the US market and its strategy to enhance production capabilities. By increasing local manufacturing, the company aims to streamline its supply chain and respond more effectively to market demands. This move is likely to bolster Medtronic's competitive edge by ensuring timely delivery of innovative products to healthcare providers.

As of November  the competitive trends in the dural arteriovenous-fistulas-treatment market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) into treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. The shift from price-based competition to a focus on technological advancements and supply chain reliability is evident. Moving forward, competitive differentiation will likely hinge on the ability to innovate and adapt to evolving market demands, with a strong emphasis on enhancing patient outcomes and operational efficiency.

## Report Scope

| MARKET SIZE 2024 | 563.9(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 605.69(USD Million) |
| MARKET SIZE 2035 | 1237.93(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.41% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Medtronic (IE), Stryker (US), Johnson & Johnson (US), Boston Scientific (US), Terumo (JP), B. Braun (DE), Abbott (US), Penumbra (US) |
| Segments Covered | Treatment Type, Procedure Type, Diagnosis Type, Patient Type, Healthcare Setting |
| Key Market Opportunities | Advancements in minimally invasive techniques enhance treatment options in the dural arteriovenous-fistulas-treatment market. |
| Key Market Dynamics | Technological advancements and regulatory changes are reshaping treatment approaches in the dural arteriovenous-fistulas-treatment market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US dural arteriovenous-fistulas-treatment market?**
A: The market valuation was $563.9 Million in 2024.

**Q: What is the projected market size for the US dural arteriovenous-fistulas-treatment market by 2035?**
A: The market is expected to reach $1237.93 Million by 2035.

**Q: What is the expected CAGR for the US dural arteriovenous-fistulas-treatment market during the forecast period 2025 - 2035?**
A: The expected CAGR is 7.41% during the forecast period.

**Q: Which treatment type had the highest valuation in the US dural arteriovenous-fistulas-treatment market?**
A: Endovascular Intervention had the highest valuation, ranging from $200.0 Million to $450.0 Million.

**Q: What are the key players in the US dural arteriovenous-fistulas-treatment market?**
A: Key players include Medtronic, Stryker, Johnson & Johnson, Boston Scientific, Terumo, B. Braun, Abbott, and Penumbra.

**Q: What is the valuation range for surgical excision in the procedure type segment?**
A: Surgical Excision is valued between $169.93 Million and $373.79 Million.

**Q: How does the market valuation for pediatric patients compare to adult patients in the US dural arteriovenous-fistulas-treatment market?**
A: The valuation for adult patients ranges from $400.0 Million to $850.0 Million, while pediatric patients range from $163.9 Million to $387.93 Million.

**Q: What is the valuation range for digital subtraction angiography in the diagnosis type segment?**
A: Digital Subtraction Angiography is valued between $213.9 Million and $437.93 Million.

**Q: Which healthcare setting has the highest valuation in the US dural arteriovenous-fistulas-treatment market?**
A: Hospitals have the highest valuation, ranging from $226.56 Million to $487.12 Million.

**Q: What is the projected growth trend for the US dural arteriovenous-fistulas-treatment market?**
A: The market is likely to experience robust growth, with a projected valuation increase to $1237.93 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-dural-arteriovenous-fistulas-treatment-market-18310*